Biomechanical Investigation of Symptomatic FAI and Two Groups of Asymptomatic Controls
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Feb 14, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called femoroacetabular impingement (FAI), which causes hip pain due to abnormal contact between the hip joint's bones during movement. The researchers want to better understand how the structure of the spine and pelvis affects hip motion and contributes to FAI symptoms, especially in young adult males. They will use advanced imaging techniques to look at bone movement and compare individuals who have symptoms with those who do not, even if they have similar bone shapes.
To join the study, participants must be males aged 21 to 35 years old. There are specific requirements based on their hip condition: some must have a specific type of FAI (called CAM-FAI), while others must be asymptomatic controls with similar bone structures or healthy controls with no symptoms at all. Participants can expect to undergo detailed imaging and motion analysis to help researchers learn more about this condition and improve diagnosis and treatment options in the future. It's important to note that those with certain types of joint problems, like osteoarthritis or a different type of FAI, won't be eligible for this trial.
Gender
MALE
Eligibility criteria
- Exclusion Criteria:
- • - Participants in all three study groups will be excluded if x-ray scans shows a pincer FAI morphology or radiological sign of osteoarthritis.
- Inclusion Criteria:
- • All participants will be males aged between 21 and 35 years old.
- • For symptomatic CAM-FAI patients
- • 1. The presence of CAM-FAI morphology at the head-neck junction of the femur
- • 2. Alpha angle \>60
- • 3. Reduced hip internal rotation (IR\<15)
- * For asymptomatic CAM controls:
- • 1. Exhibit asymptomatic CAM on x-ray scansAlpha angle \>60
- * For Healthy control group:
- • 1. Exhibit no symptoms or abnormal morphologies of the proximal femur (Alpha angle \>60 , IR\>15).
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Vlaams Brabant, Belgium
Patients applied
Trial Officials
Stijn Ghijselings, MD
Principal Investigator
Universitaire Ziekenhuizen KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported